Search
Ensysce Biosciences Inc
ENSCAdd to Watchlist
0.284USD
-0.018-5.87%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
2.63MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-5.87%
5 Days
-5.62%
1 Month
+7.17%
6 Months
-69.79%
Year to Date
-69.13%
1 Year
-87.71%
Key Figures
0.290Open
0.300High
315.62KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
3.40%Turnover Ratio
0.302Prev. Close
0.282Low
69.19KTurnover
LossP/E Static
-7.75P/B
0.00%Div Yield TTM
-347.72%ROA
2.75052wk High
0.67Volume Ratio
-7.99MNet Profit
9.28MShares
-3.1104EPS TTM
0.86Beta
-870.19%ROE
0.23052wk Low
5.97%Amplitude
100.00%Gross Margin
2.63MMarket Cap
0.19Reward/Risk
6.05%Risk Rate
TradingKey Stock Score of Ensysce Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Ensysce Biosciences Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 249 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 16.45.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ensysce Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ensysce Biosciences Inc Highlights
StrengthsRisks
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 127.15% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.07M.
Overvalued
The company’s latest PE is -0.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 494.53K shares, decreasing 27.86% quarter-over-quarter.
Analyst Rating
Based on
0
analysts
--
Current Rating
16.450
Target Price
+5352.44%
Upside Space
Ensysce Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ensysce Biosciences Inc Info
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Ticker SymbolENSC
CompanyEnsysce Biosciences Inc
CEOKirkpatrick (Lynn D)
Websitehttps://ensysce.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Ensysce Biosciences Inc (ENSC)?
The current price of Ensysce Biosciences Inc (ENSC) is 0.28.
What is the symbol of Ensysce Biosciences Inc?
The ticker symbol of Ensysce Biosciences Inc is ENSC.
What is the 52-week high of Ensysce Biosciences Inc?
The 52-week high of Ensysce Biosciences Inc is 2.75.
What is the 52-week low of Ensysce Biosciences Inc?
The 52-week low of Ensysce Biosciences Inc is 0.23.
What is the market capitalization of Ensysce Biosciences Inc?
The market capitalization of Ensysce Biosciences Inc is 2.63M.
What is the Earnings Per Share (EPS TTM) of Ensysce Biosciences Inc (ENSC)?
The Earnings Per Share (EPS TTM) of Ensysce Biosciences Inc (ENSC) is -3.98.